Benefit-risk assessment of tumour necrosis factor antagonists in the treatment of psoriasis. [electronic resource]
Producer: 20110322Description: 1349-58 p. digitalISSN:- 1365-2133
- Adalimumab
- Adult
- Anti-Inflammatory Agents -- adverse effects
- Antibodies, Monoclonal -- adverse effects
- Antibodies, Monoclonal, Humanized
- Etanercept
- Female
- Humans
- Immunoglobulin G -- adverse effects
- Infliximab
- Male
- Middle Aged
- Psoriasis -- drug therapy
- Receptors, Tumor Necrosis Factor -- therapeutic use
- Risk Assessment -- methods
- Tumor Necrosis Factor-alpha -- antagonists & inhibitors
No physical items for this record
Publication Type: Journal Article; Research Support, Non-U.S. Gov't; Review
There are no comments on this title.
Log in to your account to post a comment.